Firefly expands its leadership team as it nears the closing of its merger with WaveDancer
Firefly Neuroscience, Inc. (“Firefly” or the “Company”), a pioneering artificial intelligence (“AI”) driven company developing innovative neuroscientific solutions to improve outcomes for patients with mental illnesses and neurological disorders, today announced the expansion of its leadership team with the appointment of Samer Kaba, M.D. as its Chief Medical Officer, as it nears the closing of its planned merger with WaveDancer, Inc. (NASDAQ: WAVD).
“We are delighted to welcome Samer to our executive management team,” said Jon Olsen, Chief Executive Officer of Firefly. “His proven track record in the neuroscience drug development space will be instrumental in advancing our mission to promote brain health through our BNA™ platform. His leadership and strategic insights will be invaluable as we continue to push forward to provide patients with better outcomes for brain health.”
Prior to joining Firefly, Dr. Kaba held multiple leadership positions in the pharmaceutical industry and served as Chief Medical Officer of various biotechnology companies, where he led the development of multiple pharmaceutical products. In addition to his large expertise in drug development, medical affairs, and regulatory sciences, Dr. Kaba has over 20 years of experience in managing patients with neurological conditions. Dr. Kaba is a board-certified neurologist with additional training in Neuro-immunology (Multiple Sclerosis) at the State University of New York at Buffalo, and in Neuro-oncology at the University of Texas M.D.
Explore AITechPark for the latest advancements in AI, IOT, Cybersecurity, AITech News, and insightful updates from industry experts!
